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ABSTRACT 
Intravesical immunotherapy, chemotherapy, and neoadjuvant systemic chemotherapy are among 
the most frequent therapeutic procedures to treat malignancies of the urinary bladder.  These 
treatment modalities produce reactive morphologic changes in the urothelium that can mimic 
urothelial carcinoma in situ, urothelial dysplasia or true invasive urothelial neoplasia. Mitomycin 
C used after transurethral resection of bladder tumor to reduce recurrences, BCG intravesical 
immunotherapy to treat high risk non-muscle invasive bladder cancer and urothelial carcinoma in 
situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific 
survival some of the causes of therapy related atypia  in urinary bladder. In addition, a number of 
systemic drugs in use to treat other systemic diseases, such as cyclophosphamide used to treat 
certain auto-immune disorders or hematologic malignancies, or the anesthetics ketamine 
increasingly used as illegal recreational drug, may produce similarly relevant atypical changes in 
the urothelium, and therefore, need to be differentiated from intraepithelial neoplasia. 
Immunohistochemical approach to reactive urothelium from CIS using CK20, p53, and CD44 
may also be of utility in the pos-therapy scenario.   
INTRODUCTION 
About 70% of newly diagnosed urothelial bladder cancer cases are classified as non-muscle-
invasive (NMIBC) which includes Ta ( non-invasive) and T1 (subepithelial connective tissue 
invasion) tumors and carcinoma in situ (CIS).
1
 Urothelial carcinomas of the bladder are
frequently treated by a combination of surgery, intravesical immunotherapy, chemotherapy or 
radiation-therapy using specific pathology-based protocols, mostly grade and stage.
2-86
 For
instance, intravesical Mitomycin C to reduce tumor’s recurrences or intravesical BCG (Bacillus 
Calmette-Guerin) immunotherapy will follow the diagnosis of high grade non-muscle invasive 
bladder tumor in addition to transurethral resection of the bladder tumor. According to current 
guidelines, these patients receive frequent cystoscopies with mapping biopsies to evaluate 
therapeutic efficacy or to diagnose potential urothelial alterations.
2
 The level of cellular atypia
may simulate intraepithelial neoplasia, or may represent areas of true residual neoplastic disease. 
18
 The pathologist should keep in mind that pos-therapeutic diagnosis of residual and recurrent 
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bladder cancer is a great challenge. 
2,12
 Alternative therapeutic approaches, such as gene therapy
or different forms of immunotherapy alone or in different combinations with chemotherapy have 
been recently adopted although remain as experimental procedures.
2-12
Neoadjuvant systemic platinum-based chemotherapy is increasingly applied in most 
institutions before surgery in an attempt to improve cancer specific survival.
42-47 
 However, there
is limited data on tissue and cellular changes related to this therapy, both in the tumor itself and 
the non-neoplastic urothelium. 
2-20
The aim of this paper is to review the morphologic urothelial changes induced by 
traditional and novel therapeutic procedures in use to treat bladder urothelial cancer and to 
provide morphologic and immunohistochemical clues that maybe useful in resolving difficult 
differential diagnoses that could be encountered in such settings.  Changes induced by systemic 
chemotherapy in the urothelium are also presented. The following intravesical, local and 
systemic therapeutic procedures are reviewed: 
 Chemotherapy
 Immunotherapy
 Radiation Therapy
 Surgery
 Photodynamic and laser therapy
 Gene therapy
 Other therapy related alterations
CHEMOTHERAPY 
Chemotherapeutic agents frequently used either intravesically or systemically, may produce 
urothelial reactive atypical changes that occasionally might be mistaken for urothelial carcinoma 
in situ.
2-32
INTRAVESICAL CHEMOTHERAPY 
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Intravesical therapy is applied in order to eradicate existing disease, to prevent tumor 
recurrences, and to prevent tumor progression.
6, 12-16
 Nowadays, the main goal for intravesical
chemotherapy is to limit the number of recurrences after TUR of bladder tumor, most frequently 
by bladder instillations of mitomycin C after resection. 
6, 12-16
Mitomycin C 
Mitomycin C is currently the most frequent intravesical chemotherapeutic agent in use.  It 
is an antitumor antibiotic which induces inter and intra-strand cross links in DNA molecules. It 
has been shown to degrade DNA and inhibit its synthesis, thus making it effective during the late 
G1 and S phases of the cell cycle. 
6, 12-16
 Table 1
Mitomycin C produces histologic and cytologic alterations in normal urothelium including 
cellular exfoliation, denudation, and atypical changes in the superficial umbrella cells.
2-16
 Such
cells become large, vacuolated and often multinucleated with small nucleoli. The cellular 
alterations are not specific and may also be caused by chronic irritation due to inflammation, 
catheterization, and instillation of saline solutions. These atypical cells can persist in cytologic 
specimens for a variable period after discontinuation of therapy. Less significant abnormalities 
may be seen in the deeper layers of the urothelium. Limited data suggest that 
immunohistochemical expression of p53, CD44, and CK20 in this setting is similar to what is 
seen in reactive urothelium. Furthermore, AMACR is frequently negative in reactive atypia in the 
post-therapy setting thus suggesting a role of AMACR in combination with p53, CD44 and 
CK20  in differentiating reactive atypia vs. CIS after therapy.
59-,61
A hemorrhagic and necro-inflammatory process similar to chemical cystitis follows 
intravesical administration of mitomycin C. There is often a histiocytic response that extends 
deep into the bladder wall with isolated single and clustered macrophages. Mitomycin C may 
also initiate an eosinophilic cystitis. Fibrosis with scarring and bladder wall calcification has 
been documented in rare cases after long-term topical therapy.
2-16 
Fig 1
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In case of persistent papillary neoplasia, Mitomycin C suppresses tumor growth and limit 
progression, but does not eradicate cancer. It is thought to act as surface abrasive to destroy the 
tips of papillary fronds, resulting in stubby papillae lined by neoplastic cells or fully denuded 
papillae. Urothelial denudation makes recurrences difficult to detect cystoscopically and 
document histologically but urothelial dysplasia and carcinoma in situ have been found in von 
Brunn’s nests in case of residual disease.12-16
Other topical agents 
A range of other intravesical chemotherapeutic agents remain useful in selected patients. 
Thiotepa (triethylenethiophosphoramide), an alkylating agent, is the oldest of the intravesical 
chemotherapeutic agents still in use. Its mechanism of action involves the formation of covalent 
bonds between DNA /RNA and proteins which thus results in nucleic acid synthesis inhibition. 
Thiotepa also reduces cell adherence with a direct cytotoxic effect.
14
 Thiotepa and Mitomycin C
produce identical histologic and cytologic alterations in the normal urothelium and the bladder 
wall.
12-16
Doxorubicin (Adriamycin), epirubicin, valrubicin,  ethoglucid (epodyl), cisplatin and 
mitoxantrone are known to cause alterations in the bladder mucosa.
2-16 
The frequency varies from
agent to agent. For example, there is a 21 to 25% incidence of epirubicin  and doxorubicin-
induced cystitis, respectively.  Cystitis ranging from 3-56% has been seen with ethoglucid. 
Gemcitabine, a pyrimidine analog with a broad spectrum of antitumor activity is gaining activity 
as second line intravesical chemotherapy agent.
2-16
The full morphologic description of the changes in the urothelium and in the lesions 
being treated specific to these agents is not available, but limited data from our experience 
suggest pathologic alterations similar to the changes described for mitomycin C and Thiotepa. 
Systemic chemotherapy 
Several agents are systemically administered to treat different neoplastic and non-
neoplastic disorders. Among these agents, cyclophosphamide is known to severely affect the 
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urothelium. Other agents as ketamine are increasingly used as illegal recreational drug may 
produce ketamine cystitis with severe changes in the urothelium with potential to mimic of 
urothelial CIS. 
17-34
 Neoadjuvant systemic platinum-based chemotherapy is increasingly applied
before cystectomy in attempt to improve cancer specific survival. The pathologists is increasingly 
asked to evaluate the efficacy of such treatment and recognize the reactive  lesions that could be 
associated . Table 2 
Cyclophosphamide 
Cyclophosphamide is an alkylating agent used to treat a variety of malignancies including 
lymphoproliferative disorders, as well as diseases such as systemic lupus erythematosus, 
rheumatoid arthritis, organ transplantation,  or nephrotic syndrome.
17-34
 Active metabolites,
acrolein and phosphoramide concentrate in the urine and thus be in contact with the urothelium. 
The drug is a toxic to the urinary bladder that increases the risk for urinary bladder cancer for 
years after therapy.
17-34
 Cyclophosphamide causes cell division arrest that results in large, bi-or-
multinucleated cells often with bizarre nuclei resembling changes of radiation injury mimicking 
intraepithelial neoplasia. There is marked but variable cellular and nuclear enlargement. Nuclei 
are usually hyperchromatic, often eccentric with slightly irregular outlines. Nuclear pyknosis is a 
common late effect that results in loss of chromatin texture. Chromatin may be coarse but is 
usually evenly distributed. Nucleoli are single or double and are occasionally large and distorted 
with irregular and sharp edges. These architectural and cellular abnormalities of the urothelial 
cells may be mistaken for malignancy.
17-34
Systemic cyclophosphamide therapy typically induces hemorrhagic cystitis.
17-34 
Histology
also include vascular ectasia,  severe edema, and hemorrhage of the lamina propria, usually 
associated with necrosis of the epithelial lining and mucosal ulceration covered with 
fibrinopurulent exudate. In our experience, immunohistochemical expression of p53 and Ki67 is 
low, and CK20 is expressed in superficial cells of the urothelium, therefore supporting the 
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reactive nature of the pathologic changes.  Systemic cyclophosphamide therapy may induce 
reactivation of polyomavirus infection, a change that mimics dysplasia or CIS. 
17-34
Late fibrosis of the lamina propria and the muscularis propria develops in about 25% of 
cases examined at autopsy.
30-34
 Bladder wall calcification may also be seen.
28
 Hemorrhagic
cystitis may rarely occur also in busulfan treated patients. Busulfan is an alkylating antineoplastic 
drug in use to treat chronic myeloid leukemia. 
17-34
The evidence that cyclophosphamide increases bladder cancer risk is primary based on a 
series of case reports, but it seems that the risk increases with cumulative total dose of 
cyclophosphamide.
17-34 
Bladder cancer occurs, most commonly, several years after treatment of
lymphoproliferative or myeloproliferative disorders, mainly multiple myeloma, Hodgkin's 
disease and in patients receiving cyclophosphamide after organ transplantation.
17-34
 Urothelial
carcinoma is the most common form of cancer, although squamous cell carcinoma, 
adenocarcinoma, undifferentiated carcinoma, sarcomatoid carcinomas (carcinosarcoma) and even 
sarcomas have been observed.. 
17-34
Ketamine 
Ketamine cystitis shares a number of histopathological features with interstitial cystitis 
(bladder pain syndrome) including urothelial ulceration, inflammation, and variable 
degree of bladder wall fibrosis at later stage.
9
 However, the degrees of bladder wall
inflammation and fibrosis are more severe in ketamine cystitis thus resulting in 
contracted bladder and upper urinary tract damage with hydronephrosis, vesicoureteral 
reflux, and recurrent urinary tract infection.   
In these cases, the urothelium may be diffusely denuded and ulcerated with 
prominent granulation tissue, congested vessels, lymphocyte infiltration and variable 
number of eosinophils in the lamina propria. Ketamine related reactive urothelial 
changes may mimic carcinoma in situ.
10
 Interestingly, most of these cases were negative
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for cytokeratin 20 but had high p53 immunoreactivity and moderate to high levels of 
Ki67 reactivity, a fact to keep in mind in the differential with CIS..  
Different mechanisms to develop ketamine cystitis have been proposed.
11
 These 
include: (1) direct effect of ketamine or its metabolites on bladder wall interstitial 
tissues; (2) microvascular changes in the bladder and possibly kidney by ketamine 
and/or its metabolites; (3) indirect effect of ketamine by causing an autoimmune 
reaction against the urothelium and submucosa, due to circulating ketamine or urinary 
ketamine and its metabolites; and (4) bacterial infection 
Neoadjuvant systemic chemotherapy 
Neoadjuvant platinum-based chemotherapy is now part of the management of patient 
with high risk bladder cancer prior to cystectomy in cT2-T4cN0M0 tumors. 
Neoadjuvant chemotherapy may result in significant tumor response and thus necessitate 
careful macroscopic assessment for residual tumor.
43-47
 At cystectomy patients that 
received neoadjuvant chemotherapy are often down staged to be pT0, a finding which is 
associated with improved survival.
43-47
  Improved survival following neoadjuvant 
chemotherapy has also been studied for variant histologic types with similar results. 
46 
A “tumor regression grade” by comparing the tumor in the TURBT with residual tumor 
in the cystectomy following neoadjuvant chemotherapy has been developed. The grade 
was based on the amount of residual tumor with respect to the size of the TUR of 
bladder tumor site scar. 
23
 In this system, 3 grades were assigned: TRG1 – no 
identifiable residual tumor (complete response), TRG2 – residual tumor occupying < 
50% of the area of fibrosis and TRG3 – residual tumor overgrowing or occupying ≥ 
50% of the fibrotic area. The TRG correlated significantly with overall survival. Fig 2  
Wang et al
 24
, more recently, compared cystectomy findings in patients with TUR of 
bladder tumor alone compared with TUR of bladder tumor with neoadjuvant 
chemotherapy and found significant histologic overlap between the two groups. The 
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only morphologic features that were significantly different between the two were the 
presence of hyalinization of the wall and fewer foreign body giant cells in the 
neoadjuvant chemotherapy patients. They also noted more frequent lymph node 
changes, in particular hyalinization in patients receiving neoadjuvant chemotherapy.  
Associated xanthoma may also be seen in samples of the bladder, mainly after 
neoadjuvant chemotherapy.
 63 
Rarely, we have seen lymphatic vessels dilatation of
variable intensity in cystectomies from patients receiving neoadjuvant chemotherapy. 
Fig 3 
Some patients treated by neoadjuvant systemic chemotherapy present residual 
areas of urothelial CIS or papillary NMIBC (cTa, cT1) with emerging data suggesting 
that they carry no prognostic differences when compared with pT0 cases. 
47
A limited number of studies had reported tissue biomarkers with the potential of 
being predictors of response to systemic neoadjuvant chemotherapy. Of particular 
interest is Bcl-2 overexpression in chemotherapy-naive primary bladder cancer which is 
related to poor chemotherapy response and therefore, might assist to select likely non-
responders to platinum-base chemotherapy. Also, the combination of GDPD3 and 
SPRED1 resulted as independent predictor of neoadjuvant chemotherapy response 
status in muscle-invasive bladder cancer. 
48-49,51
IMMUNOTHERAPY 
Intravesical BCG  
Intravesical immunotherapy is used to eradicate residual CIS after TUR and prevent tumor 
recurrence. BCG offers high rates of durable complete response. 
39-42
 BCG intravesical
instillations have been shown to activate macrophages, NK cells, B cells, and various T cells 
(CD4+, CD8+) both in vitro and in vivo. BCG treatment shows that BCG can stimulate the 
urinary expression of different interleukins (IL-1, 2, 4, 6, 8, 10 and 12), TNF-α, GMCSF, IP-10 
and IFN-γ. In particular, IFN-γ seems to be a critical mediator of anti-mycobacterial infection.8,52
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Antitumor efficacy of BCG appears to depend on a cell-mediated T helper cells immune 
response. BCG binds to bladder wall in areas showing a reduced protective glycosaminoglycan 
layer, such as those involved by CIS and other “injured” sites, thereby exerting a somewhat anti-
tumor-specific adhesion.
52 
Macrophages, dendritic cells, and even tumor cells internalize and
process BCG, thus presenting it to other host cells which activates a Major Histocompatibility 
Complex class II linked cascade of a local immune response. Table 3 
Pathologic changes associated with BCG therapy include acute and chronic 
inflammation surrounding non-caseating epithelioid granulomas. Typically, the 
superficial lamina propria contains round or ovoid small granulomas composed of 
epithelioid histiocytes and lymphocytes. Occasionally, the granulomas are poorly 
formed and one may see a few multinucleate giant epithelioid histiocytes admixed with 
lymphocytes.  BCG therapy also produces a pattern of reactive atypia in urothelium 
associated with denudation, ulceration and the posterior healing. Fig 4 Acid-fast stains 
only rarely reveal the presence of mycobacteria. 
2,8, 39-42
 Immunohistochemical
expression of p53, CD44, and CK20 is similar to what is seen in reactive urothelium; 
AMACR is frequently negative in post-therapeutic reactive atypia. 
59-61
Rare examples of severe local or systemic complications associated to BCG therapy have 
been described in patients, usually referred to as “BCG-itis”, severe enough to deserve anti-
tuberculous therapy. The role of the pathologists in this particular scenario is to diagnose the 
lesion by finding epithelioid granulomas that can be caseating. 
Immunotherapy agents other than BCG 
A number of immunotherapeutic agents have been investigated for the prophylaxis of superficial 
bladder cancer, including recombinant interferon-.4 Interferons are known to have antiviral and
direct anti-proliferative activity, regulate differentiation,  activate immune effector cells,  inhibit 
angiogenesis, induce cytokine production, and enhance tumor associated antigen expression.
4,52
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Bladder cancer cells express high levels of interferon- receptor with higher receptor densities in 
high grade carcinomas. Intravesical recombinant interferon- increases the cytotoxic activity of T 
lymphocytes and NK cells by increasing infiltration of these cells into the bladder wall which 
improves immune cell activity for 3 to 6 months.
 52
 Therefore, urothelial carcinoma cells are
susceptible to the attack from cytotoxic T lymphocytes which also directly inhibits proliferation 
of tumor cells.
4
 Most of these treatments currently remain experimental.
Pathologic changes related to these agents are non-specific. They include edema of the 
lamina propria and perivascular collections of inflammatory cells, mainly lymphocytes, 
neutrophils and eosinophils. 
Intravesical vaccinia virus has also been investigated as immunotherapy for bladder 
cancer.
5,8
 The limited number of reported cases has shown  significant mucosal and submucosal
inflammatory infiltration, characterized by lymphocytes, eosinophils, plasma cells, and dendritic 
cells. Nuclear features that suggest viral effect may also be present in some cells. 
Novel anti PD-L1 associated targeted immunotherapy is emerging in personalized therapy 
with bladder cancer showing important reduction on tumor burden. Data on the morphologic 
effect of anti-PDL1 on the treated urothelium is currently lackinge.
37,38
RADIATION THERAPY 
Twenty-percent of bladder cancer patients present with muscle invasive disease at time of 
diagnosis and are subsequently treated by radical cystectomy or Cystoprostatectomy with or 
without preoperative neoadjuvant chemotherapy.
2-12
 Definitive radiation therapy has been used
for muscle invasive bladder cancer with evidence supporting that patients can maintain a 
functional bladder and achieve durable local control without a compromise in survival. In the 
past few decades, radiation therapy has been used in patients who either refused or were not 
suitable for radical cystectomy, or in cases using bladder preservation protocols. Urothelial CIS 
and low grade disease are less responsive to radiation than high grade tumors. 
2-12
 Table 4
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Significant alterations may be seen in the bladder wall as a result of radiation therapy 
applied to other pelvic diseases like prostate, gynecologic or rectal cancers. The mechanism by 
which such effect occur remains poorly understood, but most probably is the result of damage 
incurred to the blood supply. Fig 5 
Pathologic analysis shows variable morphologic alterations in the bladder mucosa 
as result of radiation.  Main changes include acute and chronic radiation cystitis with 
mucosal ulceration and denudation and late fibrosis with bladder contracture. 
53-59
Radiation therapy results in cellular and nuclear enlargement with large nuclei, frequent 
multinucleation and vacuolization with low nuclear-cytoplasmic ratio.  The morphology 
of these degenerative nuclear features is usually recognized by the practicing pathologist 
as radiotherapy related and degenerative in nature. A reactive, tumor-like epithelial 
proliferation with nodules of squamoid epithelium pushing into the lamina propria 
without evidence of true infiltrative growth, associated with hemorrhage, fibrin deposits, 
fibrinoid vascular changes and multinucleated stromal cells is frequently seen at time of 
histologic evaluation.
53-59
  An extreme form of this tumor-like reactive lesion has been
reported as pseudo-carcinomatous hyperplasia, a rare lesion initially believed to be 
radiation related, but that may also be seen in patients without previous history of 
radiation. 
58,59
 Pseudo-carcinomatous hyperplasia consists of proliferative, pseudo-
infiltrative urothelial nests within the stroma. This late phase of radiation injury usually 
occurs months or years following ionizing radiation. A characteristic background of 
radiation therapy– related changes with dilated thrombosed vessels, edema, reactive-
appearing endothelial and stromal cells, and hemorrhage, can provide clues to the 
diagnosis, but known previous history of radiation therapy is essential. 
58-59
 The main
differential diagnoses of pseudo-carcinomatous hyperplasia include invasive urothelial 
carcinoma and the nested variant of urothelial carcinoma; morphologic features, such as 
the presence or absence of background therapy-related changes and the architecture and 
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cytologic atypia of the nests can help distinguish pseudo-carcinomatous hyperplasia and 
carcinoma.
58,59,62 
No specific immunoprofile has been described to differentiate pseudo-
carcinomatous hyperplasia and other radiation-therapy related atypia of the urothelium 
from carcinoma but some authors have suggested that TERT promoter mutation analysis 
might be used to differentiate pseudosarcomatous hyperplasia from its malignant 
mimickers (urothelial carcinoma including nested carcinoma).
54
Available data suggests that immunohistochemical expression of p53, CD44, and 
CK20 is similar to what is seen in reactive urothelium. 
59-61 
Table 5. α-Methylacyl-CoA
racemase, a tumor-associated marker that is expressed in a subset of high-grade 
urothelial carcinomas has been recently investigated as differential biomarker between 
reactive atypia and urothelial carcinoma in situ. 
60,61
 In one large study, AMACR was
able to detect only 50% of CIS in a pos-therapy setting, but benign and reactive 
urothelium (with and without a history of therapy) showed negative AMACR staining in 
all the cases (100%). The use of AMACR might have some value in differentiating 
reactive atypia vs. CIS after radiation therapy.
 60,61
Tissue other than urothelium is hemorrhagic with deposits of fibrin and mesenchymal cells 
often large and multinucleated (giant cell cystitis). Extensive scarring of the bladder wall is 
common. An important long-term effect of radiation therapy is de novo radiation-induced urinary 
bladder cancer, commonly an urothelial or squamous cell carcinoma. Rare examples of 
sarcomatoid carcinoma (or carcinosarcoma) or true sarcoma of the urinary bladder have been 
reported. 
52-59
Brachytherapy, a form of local radiation therapy used for prostate cancer may rarely 
produce atypical changes in the urethra that might be misdiagnosed as malignancy.  The 
morphology of this alteration is similar to what is seen in the bladder urothelium with cellular 
and nuclear enlargement and streaking nucleoli, but the nuclear-to-cytoplasmic ratio remains 
low. Some squamoid cellular appearance may also be present.  Degenerative nuclear features are 
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less commonly seen at the stage in which diagnostic biopsy is performed. We have seen rare 
lesions with pseudo-papillary architecture in the urethra suggesting urothelial neoplasia, however 
the clinical and morphologic background assists in recognizing the benign nature of such 
radiation therapy related reactive lesion. 
SURGERY 
The urinary bladder may show a variety of surgery-related changes. These can be divided into 
three groups: pathological changes associated with transurethral resection of the bladder, suture 
granuloma and related lesions, and pathological changes associated with bladder augmentations 
and intestinal conduits.
75
 Table 6
Pathological changes associated with TUR 
Transurethral resection of the bladder wall is followed by an intense necro-inflammatory reaction 
followed by non-specific granulomatous reaction, but also by formation of necrotizing palisading 
granuloma resembling rheumatoid nodule (postsurgical necrobiotic granuloma) and foreign 
body-type granuloma eventually resulting in fibrous scarring with occasional dystrophic 
calcification and the presence of xanthoma cells at a later stage.
3
A relevant tumor-like lesion with potential of being misdiagnosed as malignancy is the 
postoperative spindle cell nodule (PSCN), an uncommon lesion in the lower genitourinary tract 
that develops within 3 months of a surgical procedure. Fig 6.  Most bladder cases follow 
transurethral resection. Macroscopically, PSCN appears a friable occasionally polypoid mass.  
Microscopically, it consists of intersecting fascicles of spindle cells which often display 
conspicuous numbers of mitotic figures, but none are atypical.
83,87-89
  The proliferating cells have
the cytologic characteristics of Myofibroblasts. PSCN belong to the spectrum of myofibroblastic 
proliferations that may be seen along the urinary tract. There is usually a delicate network of 
small blood vessels, mild to moderate edema, acute and chronic inflammation, small foci of 
hemorrhage and variable extent of myxoid change.  Cellular atypia may be present, but the cells 
do not exhibit marked cytologic abnormalities.  History of a recent operation is the major 
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diagnostic clue and points toward and exuberant reactive proliferation. 
83,87-89
 Outcome is
invariably benign but lesions may rarely recur. PSCN may be mistaken as leiomyosarcoma, 
Kaposi's sarcoma or other sarcomas.  PSCN displays cytokeratin immunoreactivity in about 80% 
of cases, whereas this is an uncommon finding in leiomyosarcoma of the bladder. By 
immunohistochemistry, the spindle cells react with vimentin, desmin and actin. In about 50% of 
cases the cells react with the antibodies to the anaplastic lymphoma kinase (ALK-1) which may 
support the diagnosis.
83,87-89 
Fig 7
Suture granuloma  
Suture granuloma may rarely produce a tumor-like mass in or adjacent to the bladder in 
response to silk sutures introduced at the time of herniorhaphy or other surgical 
procedure.
90-93
  The process most frequently occurs in the bladder wall or perivesical
tissues. Bladder neoplasm was the clinical impression in most of reported cases, and the 
patients presented with variable urinary symptoms, including hematuria, frequency, and 
dysuria.  Microscopically, there is a predominantly histiocytic reaction to suture with 
foreign body-giant cells and varying degrees of fibrosis and chronic inflammation.  
90-93
Bladder augmentation and intestinal conduits 
Orthotopic neo-bladder with ileal segments is the elective technique in the reconstruction of the 
urinary passages following radical cystectomy.
 94-98 
Pathological changes in the intestinal mucosa
have practical importance because the histological modifications may alter the functional 
characteristics of the mucosa through metaplastic and reactive changes secondary to prolonged 
contact with urine. Rarely, the alteration may lead to secondary malignancies.  Most patients had 
developed adenocarcinoma, high grade urothelial carcinoma, undifferentiated sarcoma or small 
cell undifferentiated carcinoma. 
94-98 
 Fig 8 Examples of adenomatous polyp and Adenomatoid
tumor of the ileal conduit are on record.
95,98
PHOTODYNAMIC AND LASER THERAPY 
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Photodynamic therapy 
Photodynamic therapy based on local or systemic administration of photosensitizers 
(hematoporphyrin derivatives) is a form of focal therapy applied to bladder cancer that can 
achieve a high initial complete response rate, especially in CIS treatment, but the observed 
generalized cutaneous photosensitivity that appears in some patients makes the procedure of 
limited applicability.
 65-71
Severe local irradiative symptoms that may persist for months are
frequent, and some patients may develop bladder contracture. When administered systemically, 
these photosensitizers accumulate in tumor and only to some extent if any in normal tissue. They 
are then  activated by light leading to tumor necrosis while preserving non-neoplastic tissues. The 
photosensitizer also accumulates in the stroma and the vessel wall suggesting ischemia as an 
additional mechanism of action. Therapy response is typically noted one or two days after 
treatment.
65-71 
Table 7
Pathology features show coagulation necrosis sometimes with hemorrhagic necrosis 
sharply demarcated from the non-neoplastic tissue.
 65-71
 Early morphologic changes observed
include intravascular coagulation and adjacent tumor cell necrosis. Adjacent normal, non-
neoplastic tissue may show moderate to severe edema but necrosis is rare. Other findings include 
rare spindle cell artifact of urothelial cells and dystrophic calcification. 
65-71
Laser therapy 
The neodymiumYAG laser is most commonly. Flexible fibers can usually be inserted through 
standards cystoscopes, or through cystoscopic equipment modified for use with laser fibers. 
72-74
Lasers are mostly in use to treat patients with recurrent low grade Ta tumors as tissue is no longer 
available for histological evaluation.
72-74 
One advantage of the laser is that it allows for
transmural coagulative necrosis without perforation and extravasation. The l necrotic area is 
sharply delimited from surrounding tissue. The endothelial cells in the tissue adjacent to cancer 
tissues may acquire atypical appearance, and the pathologists should avoid misdiagnosis these 
cells as residual cancer. 
72-74
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GENE THERAPY 
Gene  therapy and tumor vaccine studies have been shown to be effective in animals by 
increasing the sensitivity of bladder cancer cells to chemotherapeutic agents.
84-86
 This finding
support the combined regimen of gene therapy with intravesical chemotherapy as a potential tool 
for bladder cancer treatment. However, currently this procedure is considered experimental.
 5,84-86
Table 8 
Very few studies addressed the cytopathic effects of gene therapy in urothelial tumors. 
Variable degree of necrosis, more frequent in high grade tumors is the hallmark. Nuclear changes 
include loss of chromatin details and nucleoli in the earlier stages. In the late stages, the nuclei 
shrink, become pyknotic, and acquire a spindled morphology instead of being round to ovoid, 
and dead cells show dark, dense, pyknotic or comma-shaped nucleus with no nuclear detail. 
Bizarre hyperchromatic nuclei may be focally present. 
5,84-86
The urothelium is rarely affected by necrosis, but contains an intense chronic inflammatory 
infiltrate of mostly B lymphocytes. Some lymphocytic infiltration may be seen at the 
tumor/normal urothelium interface or inside the tumor itself. Macrophages are abundant within 
tumor with higher frequency in areas of necrosis. Injection sites with hemorrhagic foci and 
foreign body-type giant cell reaction may be identifiable.
 5,84-86
Data on the histological changes resulting from methods of gene therapy other than tumor 
suppressor gene therapy (e.g., pro-drug activation, immuno-modulatory, and anti-angiogenesis) 
are not available.  
OTHER THERAPY RELATED ALTERATIONS 
Chemical cystitis is nowadays a rarity. Most cases reported are related to intravesical 
instillations of ether introduced into the bladder to dissolve a catheter balloon that 
resists mechanical deflation. Formalin intravesical instillation has been used to control 
bleeding in cases of hemorrhagic cystitis but is no longer in use. Bonney blue may be 
instilled in the bladder during gynecologic surgery, but failure to dilute the concentrate 
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to 0.5% working solution produces a severe chemical cystitis. Turpentine ingestion, 
excreted through the kidney creates ether-type injury, including edema, hemorrhagic 
necrosis of the bladder wall and the urothelium, and neutrophilic infiltration.  
IMMUNOHISTOCHEMISTRY IN ASSESSING THERAPY RELATED 
UROTHELIAL ATYPIA VS. UROTHELIAL CARCINOMA IN SITU 
Distinction of reactive atypia from CIS may be particularly challenging in patients 
previously treated using BCG. A helpful tip is to know that when CIS recurs, the 
morphology and immunohistochemical profile remains similar to untreated CIS.
 60,61,99
Immunohistochemical features of urothelial CIS include aberrant CK20 with 
expression seen at different levels of the urothelium, overexpression of p53 with “intense” 
nuclear staining though all cellular layers and negative staining by CD44 (isolated basal 
cells may be occasionally positive with CD44 in CIS). By contrary, atypical reactive 
urothelium shows normal CK20 immunostaining limited to the superficial cell layers in 
urothelium. In contrast, variably full-thickness positive membranous CD44 staining is 
typical of reactive urothelium, whereas p53 nuclear accumulation is undetectable or weak in 
the basal and parabasal cells of reactive urothelium.
 60,61
  Occasionally, in the post-therapy
setting we can see unexpected “paradoxical” markers’ expression, mainly in cases of 
previous radiotherapy. Most relevant pitfalls seen in post-therapy urothelial atypia include 
occasional aberrant CK20 expression seen at different levels of the urothelium instead of 
being limited to superficial umbrella cells. If this is the case, a patchy staining is seen with a 
pattern like “islands” of positivity though all cell layers separated of “islands” completely 
negative or showing only umbrella cell positivity. CD44 immunostaining is more variable 
and ranges from completely negative (positive only in basal cells) to full urothelial layers 
positivity. p53 nuclear accumulation is also variable mainly due to  differences in available 
antibodies. In some cases, one can see a pattern of staining in other cell layers in addition to 
basal and parabasal cells, when this is the case, typically most “positive-looking” cells are 
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weak and this should be considered as a negative staining pattern and therefore may support 
reactive urothelium in the appropriate clinical and morphology context. These limitations 
are relevant to daily practice of pathology. 
60,61, 99
There is limited data on utility of other markers in the setting of therapy related 
atypia of the urothelium. This includes UroVysion probe or Cyclin D3 by FISH analysis, 
and the immunohistochemical expression of p16, AMACR, HER2, or Lewis(y) antigen. All 
of them are claimed to be negative in reactive atypia and positive in CIS in variable 
proportions. Currently, it is recommended to consider these markers experimental pending 
validation studies. 
CONCLUSIONS 
Intravesical and systemic therapeutic agents, as well as other therapeutic procedures including 
mitomycin C, cyclophosphamide, BCG, platinum-based chemotherapy agents, radiotherapy, 
photodynamic and laser treatment, and gene therapy, produce a host of changes and alterations in 
the urothelium and bladder wall, some of them may mimic carcinoma. The diagnosis of these 
lesions relies on H&E based pathologic evaluation, and therefore, pathologists must be aware of 
the altered morphology secondary to therapy. Knowledge of previous history is of great relevance 
in clinical practice. Immunohistochemistry has a role as an adjunct to morphology, in 
differentiating reactive changes from CIS. A panel of p53, CK20 and CD44 is recommended to 
provide useful information but the pathologist needs to be aware of their limitations and potential 
pitfalls. A conservative approach with repeat cystoscopy and biopsy after the inflammation has 
resolved is suggested in equivocal cases.  
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Fig 1. Mitomycin C therapy related changes. (A) Intraepithelial atypia. (B and C) Denuding 
papillae. (D) Encrusted cystitis. 
Fig 2. Neoadjuvant chemotherapy before cystectomy. (A) Tumor with low response. (B and C) 
Variable degree of tumor necrosis. (D) Minor residual tumor. 
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Fig 3. Cystectomy specimen. Rare cases show lymphatic dilatation (A) mostly located at the 
lamina propria/submucosa (B). 
Fig 4. BCG related changes. (A) Partially denuded urothelium. (B) Focal epithelioid granulomas 
(B). Urothelial reactive atypia ranges from mild (C) to severe as pointed out by the arrows (D). 
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Fig 5. Radiation therapy related changes. (A) Acute radiation with hemorrhage. (B) Chronic 
radiation changes with fibrosis and vascular wall thickness. (C) Multinucleated fibroblasts seen 
in the lamina propria/submucosa after radiation therapy. (D) Pseudocarcinomatous hyperplasia 
seen in the urethra of a patient with previous brachytherapy. 
Fig 6. Postoperative spindle cell nodule 4 months after bladder TUR. 
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Fig 7. Immunohistochemistry is very helpful in differential diagnosis of spindle cell 
proliferations and tumors of the bladder. 
Fig 8. Recurrent urothelial carcinoma after bladder augmentation. Microscopic appearance (in 
inset).  
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Table 1. Pathologic features associated with mitomycin C intravesical chemotherapy 
-Atypia in the surface umbrella urothelial cells
-Denudation of the surface epithelium
-Less significant abnormalities in the deeper layers of the urothelium
-Denuding papillae of persistent papillary neoplasia
-Associated eosinophilic cystitis (mild-to-moderate; common)
-Low nuclear/cytoplasmic ratio
-Hemorrhagic cystitis (rare)
-Encrusted cystitis (rare)
Table 2. Pathologic features in systemic chemotherapy 
Cyclophosphamide 
-Atypical form of regeneration
-Necrosis of urothelium of the bladder and upper urinary tract
-Large, bizarre nuclei with coarse chromatin and small to medium sized nucleoli
-Bladder cancer following cyclophosphamide therapy (uncommon)
-Reactivation of polyomavirus infection
-Encrusted cystitis (rare)
-Hemorrhagic cystitis (currently uncommon)
Ketamine 
- Reactive urothelial changes that can mimic carcinoma in situ
-Urothelial ulceration (frequent)
-Urothelium diffusely denuded
-Lamina propria with prominent granulation tissue with congested vessels
-Inflammatory cell infiltration infiltrated predominantly by lymphocytes and a variable number of
eosinophils 
-Upper urinary tract damage and hydronephrosis
-Varying degrees of bladder wall fibrosis (late stage)
-High p53 and Ki67 (frequent).
-Normal CK20
Neoadjuvant chemotherapy 
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-Hyalinization of the wall
-Urothelium with minor atypia
-Frequent lymph node hyalinization
-Fewer foreign body giant cells
-Persistence of urothelial CIS or NMIBC (frequent)
-Xanthoma (occasional)
-Residual tumor grade: 1) No tumor; 2) Tumor <50%; 3) Tumor >50%.
Table 3. Pathologic features of intravesical immunotherapy (BCG, interferon-) 
-Bladder wall granulomatous inflammation
-Reparative urothelial atypia
-Eosinophilic cystitis (moderate-to-severe, occasional)
-Denudation of urothelium (denuding cystitis) with frequent ulceration
-Lamina propria edema (interferon-)
-Persistence of carcinoma in situ in von Brunn’s nests
-Mild perivascular inflammation with neutrophils, lymphocytes, dendritic reticulum cells, and eosinophils
(interferon-) 
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Table 4. Radiation induced pathologic features 
-Mucosal ulceration
-Denudation of urothelium
-Acute inflammatory reaction in lamina propria with atypical stromal cells
-Overall increase in urothelial cell size with normal nuclear to cytoplasmic ratio
-Bladder wall fibrosis (late stage)
-Blood vessels thrombosis
-Xanthoma (rare)
-Intensified eosinophilic staining of cytoplasm (common)
-Pseudocarcinomatous hyperplasia (uncommon)
Table 5. Immunohistochemical features of reactive urothelium vs. urothelial carcinoma in situ 
Carcinoma in Situ Reactive Atypia Normal 
CK20 ***Aberrant 
expression through 
all cell layers.  
Limited to umbrella 
cells 
Limited to umbrella 
cells 
p53 *Positive. Absent Absent 
CD44 **Absent Increased reactivity 
in all cell layers 
Limited to basal 
cells 
*
Frequently trough all cell layers 
** Basal positive cells may be seen, occasionally. 
***May be full thickness 
Table 6. Surgery related pathologic features 
-Non-specific granulomatous reaction
-Postsurgical necrobiotic granuloma
-Xanthoma (rare)
-Postoperative spindle cell nodule
-Suture granuloma
-Fistula
-Recurrent cancer in bladder augmentations and intestinal conduits
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Table 7. Pathologic features associated with photodynamic and laser therapy 
-Normal tissues range from edema to coagulation necrosis
-Coagulation necrosis
-Hemorrhagic necrosis
-Well demarcated from non-irradiated tissues
-Dystrophic calcification (occasional)
-Vascular endothelium enlargement
-Spindling artifact of urothelial cells
Table 8. Pathologic changes associated to gene therapy 
-Marked cytoplasmic vacuolization of tumor cells (early)
-Inflammatory infiltrate mainly of B-cells and macrophages
-Non-neoplastic tissues unaffected
-Apoptosis mediated tumor necrosis
